neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Company profile
Ticker
CRNX
Exchange
Website
CEO
R. Scott Struthers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CRNX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
4 Apr 24
S-3ASR
Automatic shelf registration
19 Mar 24
8-K
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
19 Mar 24
8-K
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
12 Mar 24
D
$350.00 mm in equity, sold $350.00 mm, 36 investors
11 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Mar 24
8-K
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
1 Mar 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
28 Feb 24
Latest ownership filings
4
Richard Scott Struthers
22 Apr 24
4
Dana Pizzuti
17 Apr 24
4
Richard Scott Struthers
17 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Richard Scott Struthers
8 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Stephanie Okey
2 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
4
Jeff E. Knight
26 Mar 24
4
Dana Pizzuti
22 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 144.10 mm | 144.10 mm | 144.10 mm | 144.10 mm | 144.10 mm | 144.10 mm |
Cash burn (monthly) | (no burn) | (no burn) | 19.66 mm | 17.29 mm | 13.78 mm | 13.58 mm |
Cash used (since last report) | n/a | n/a | 134.86 mm | 118.63 mm | 94.53 mm | 93.18 mm |
Cash remaining | n/a | n/a | 9.23 mm | 25.47 mm | 49.56 mm | 50.91 mm |
Runway (months of cash) | n/a | n/a | 0.5 | 1.5 | 3.6 | 3.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 177 |
Opened positions | 56 |
Closed positions | 20 |
Increased positions | 81 |
Reduced positions | 28 |
13F shares | Current |
---|---|
Total value | 2.01 tn |
Total shares | 72.93 mm |
Total puts | 563.55 k |
Total calls | 694.05 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Driehaus Capital Management | 5.13 mm | $152.63 bn |
BLK Blackrock | 4.85 mm | $144.11 bn |
Point72 Asset Management | 4.23 mm | $125.66 bn |
Wellington Management | 3.64 mm | $108.26 bn |
Vanguard | 3.41 mm | $101.33 bn |
Orbimed Advisors | 2.90 mm | $86.13 bn |
STT State Street | 2.85 mm | $84.84 bn |
Biotechnology Value Fund L P | 2.74 mm | $0.00 |
T. Rowe Price | 2.58 mm | $76.58 bn |
Paradigm Biocapital Advisors | 2.18 mm | $64.80 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Struthers Richard Scott | Common Stock | Gift | Dispose G | No | No | 0 | 350 | 0.00 | 257,485 |
15 Apr 24 | Struthers Richard Scott | Common Stock | Option exercise | Acquire M | No | No | 1.91 | 20,000 | 38.20 k | 257,835 |
15 Apr 24 | Struthers Richard Scott | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.91 | 20,000 | 38.20 k | 81,270 |
15 Apr 24 | Dana Pizzuti | Common Stock | Sell | Dispose S | No | Yes | 44.47 | 14,375 | 639.26 k | 27,786 |
15 Apr 24 | Dana Pizzuti | Common Stock | Option exercise | Acquire M | No | No | 16.89 | 14,375 | 242.79 k | 42,161 |
15 Apr 24 | Dana Pizzuti | Stock option Common Stock | Option exercise | Dispose M | No | No | 16.89 | 14,375 | 242.79 k | 177,292 |
4 Apr 24 | Struthers Richard Scott | Common Stock | Sell | Dispose S | No | Yes | 49.17 | 40,951 | 2.01 mm | 237,835 |
4 Apr 24 | Struthers Richard Scott | Common Stock | Option exercise | Acquire M | No | No | 9.28 | 40,951 | 380.03 k | 278,786 |
4 Apr 24 | Struthers Richard Scott | NQSO Common Stock | Option exercise | Dispose M | No | No | 9.28 | 40,951 | 380.03 k | 123,790 |
28 Mar 24 | Okey Stephanie | Common Stock | Sell | Dispose S | No | No | 46.38 | 17,500 | 811.65 k | 6,000 |
News
Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $55
20 Mar 24
JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $80
20 Mar 24
JonesTrading Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $56
20 Mar 24
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
19 Mar 24
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
19 Mar 24
Press releases
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Apr 24
Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
19 Mar 24
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
14 Feb 24